Goldman Sachs analyst Davin Thillainathan initiated coverage of Fisher & Paykel Healthcare with a Buy rating and A$42.70 price target The firm sees an acceleration of revenue in the company’s hospital segment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF: